IRIS
GROSSI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.461
AS - Asia 11
NA - Nord America 1
SA - Sud America 1
Totale 3.474
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.461
CN - Cina 7
SG - Singapore 4
BR - Brasile 1
US - Stati Uniti d'America 1
Totale 3.474
Salva come PNG Salva come JPEG
Città #
Genova 1.476
Genoa 1.189
Rapallo 451
Vado Ligure 335
Bordighera 10
Singapore 3
Beijing 2
Ashburn 1
São Paulo 1
Totale 3.468
Salva come PNG Salva come JPEG
Nome #
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 150
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely 141
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 140
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 120
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 116
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 108
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 107
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 106
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? 104
Exosomes: a new horizon in lung cancer 102
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 101
Understanding the checkpoint blockade in lung cancer immunotherapy 99
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 98
Gefitinib treatment outcome after progression on erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) 97
Afatinib for the treatment of non-small cell lung cancer 96
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 96
Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 93
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 92
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 89
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 87
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 86
Vinflunine for the treatment of non-small cell lung cancer 85
Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib 80
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 80
Hematopoietic growth factors in lung cancer 78
PCSK9 is a promising prognostic marker in patients with advanced NSCLC 76
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 76
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 76
Skin toxicities difference between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 74
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 73
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 72
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 61
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 60
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 57
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 56
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects 56
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer 54
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 52
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage? 51
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy” 51
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 47
Looking for results in non-small-cell lung cancer: Is bio-chemotherapy the right answer? 37
PCSK9 as a new player in cancer: New opportunity or red herring? 13
Totale 3.593
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.169
article - articoli 15.750
book - libri 0
conference - conferenze 1.419
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.338
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021646 0 0 0 214 114 12 69 64 63 63 18 29
2021/2022482 60 16 5 22 30 51 10 103 26 60 24 75
2022/2023514 42 34 9 51 85 94 0 43 78 6 67 5
2023/2024256 7 29 7 41 20 47 20 19 12 14 2 38
2024/2025877 22 52 30 53 121 92 101 185 30 48 67 76
2025/2026361 192 30 82 57 0 0 0 0 0 0 0 0
Totale 3.593